LearnGlossaryMarketStocksSuperinvestorsSign in

CRMD

CorMedix Inc.

Healthcare · $622M market cap

Verdict

We can't put a fair value on CRMD right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth5.5% a year✗
Sales growth617.0% a year✓
Free cash flow growth—?
Return on invested capital-23.5%✗

Follow CRMD

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 29, 2026: no open-market purchases and 3 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Zelnick Kaufman Beth

Chief Legal Officer · 2026-08-29

Tax withholding

$70K

Hurlburt Elizabeth

Chief Operating Officer · 2026-08-29

Tax withholding

$67K

Blum Susan

Chief Financial Officer · 2026-08-29

Tax withholding

$70K

About CorMedix Inc.

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works